KRAS and neoplasm: The prevalence of mutations was found to be relatively infrequent (i.e. alteration frequency <10%) across most tumour types except endometrial cancer and melanoma (Fig. 1A), compared to known oncogenic mutations such as KRAS or PIK3CA (Supplementary Fig. 1A, B).